Tag: ARX788

FDA, Regulations

FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer

January 4, 2021

Via: BioSpace

Ambrx announced that the U.S. Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or metastatic HER2-positive breast cancer patients who have received one or more prior anti-HER2 based regimens in the […]